Contact Media

If you have any questions, please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices

Contact Media Relations

Copenhagen joins 'Cities Changing Diabetes'

Copenhagen, Denmark, 22 August 2014 – Today, the City of Copenhagen and Novo Nordisk announces an ambitious partnership to fight the diabetes challenge in Copenhagen. The partnership is a part of the global ‘Cities Changing Diabetes’ programme, which was initiated by Novo Nordisk and first launched in Mexico City on 28 March 2014. “On a global level we know that two in three of all people with diabetes live in cities. With ‘Cities Changing Diabetes’ we hope to get cities around the world to work together to find sustainable solutions to the urban diabetes challenge. We are very pleased that Copenhagen has decided to join. In Denmark, around 89% of people with diabetes live in cities, so we hope that the solutions we find in Copenhagen can also inspire other cities in Denmark", says Lars Rebien Sørensen, CEO of Novo Nordisk.

See the release

Increased operating profit by 12%

Sales increased by 7% in local currencies and by 1% in Danish kroner to DKK 42.0 billion during the first six months of 2014 compared to the same period in 2013

7 August - Lars Rebien Sørensen, CEO: “We are satisfied with the financial results achieved in a challenging first half of 2014. Tresiba® is doing well in key markets and the DEVOTE trial continues to progress ahead of plans. This has enabled us to further shorten the timeline towards the interim analysis and a potential US launch of Tresiba®. Furthermore, with the positive opinion for Xultophy® from the EU regulatory authorities, we have passed a key milestone in bringing the first insulin and GLP-1 combination product to the market.”

Read the company announcement

See the interview with CEO Lars Rebien Sørensen on CNBC:


Xultophy® (IDegLira) receives positive opinion from EMA

25 July - The Committee for Medicinal Products for Human Use (CHMP) under EMA has adopted a positive opinion recommending marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. “We are excited about the positive opinion for Xultophy®. We believe that Xultophy® represents a new treatment paradigm with the potential to transform how type 2 diabetes is treated. We look forward to making the product available to people with type 2 diabetes in Europe,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer.

Read the company announcement

Clinical Trial Transparency

1 March - Novo Nordisk has made it easier for external researchers to get access to clinical trial data. You may read about how we conduct our clinical trials, about volunteering to participate, how we disclose trial information to the public and how researchers can access clinical trial datasets.
Read more about clinical trials.





Vienna, Austria

Novo Nordisk Stories

TBL Quarterly

24 June - What is the key to better health in India? Read the stories in the new TBL Quarterly.  

Changing Diabetes in India

11 June - In India, there are not enough healthcare professionals to meet the needs of the 65 million people with diabetes. Partnerships can change this. Find out how (PDF)